FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386421705> ?p ?o ?g. }

• W4386421705 endingPage "65" @default.
• W4386421705 startingPage "58" @default.
• W4386421705 abstract "Introduction. One of the promising strategies for the development of injectable formulations of poorly water-soluble drugs is the preparation of their nanosuspensions stabilized with albumin. A well-known example of the successful implementation of this technology is Abraxane® (nanoparticle albumin-bound paclitaxel). In the present study, this approach is used for the development of the injectable formulation of a hydrophobic etoposide prodrug. Aim. Development of the injectable formulation of a novel 4'-О-benzyloxycarbonyl derivative of etoposide (ETP-cbz) based on human serum albumin and evaluation of its cytotoxicity against breast carcinoma cells (BC). Materials and methods. The structure of ETP-cbz was confirmed by NMR spectroscopy and elemental analysis; log P was calculated in silico using Molinspiration Cheminformatics. The ETP-cbz-HSA nanoparticles were prepared by high pressure homogenization. The particle size, size distribution, and disintegration concentration were evaluated by dynamic light scattering (DLS) and atomic force microscopy (AFM). The contents of ETP-cbz and albumin in the formulation were determined by HPLC. The conversion ETP-cbz-HSA to etoposide was studied in a model medium in the presence of esterase. The cytotoxicity of ETP-cbz-HSA compared to etoposide and free ETP-cbz was assessed on BC cells (HBL-100 and MCF-7) using a colorimetric MTT assay. Results and discussion. ETP-cbz exhibited higher hydrophobicity as compared to the etoposide (log P 2.42 vs 0.7, respectively). Due to easy cleavage of the carbonate bond in the presence of esterase, ETP-cbz can be considered an etoposide prodrug. The ETP-cbz-containing HSA nanoparticles prepared by a high-pressure homogenization technique had the particle size of 110 ± 9 nm (DLS) and a low disintegration concentration of 3.0 ± 0.1 μg/mL. The drug content was 1.75 mg/mL. The nanoformulation demonstrated high cytotoxic activity in vitro against MCF-7 and HBL-100 cells that was comparable to the activity of substances etoposide and ETP-cbz. Conclusion. The obtained nanoformulation of etoposide prodrug based on albumin, suitable for injection, showed high cytotoxicity against breast cancer cells in vitro and deserves further study to assess the possibility of its use in breast cancer chemotherapy." @default.
• W4386421705 created "2023-09-05" @default.
• W4386421705 creator A5004249898 @default.
• W4386421705 creator A5007962409 @default.
• W4386421705 creator A5033968842 @default.
• W4386421705 creator A5039404683 @default.
• W4386421705 creator A5048247977 @default.
• W4386421705 creator A5054020101 @default.
• W4386421705 creator A5058080390 @default.
• W4386421705 creator A5062675094 @default.
• W4386421705 date "2023-08-30" @default.
• W4386421705 modified "2023-10-01" @default.
• W4386421705 title "Development of Injectable Formulation of 4’-O-benzyloxycarbonyl-etoposide Derivative Based on Human Serum Albumin for the Chemotherapy of Breast Cancer" @default.
• W4386421705 cites W1488635614 @default.
• W4386421705 cites W2020011827 @default.
• W4386421705 cites W2033421322 @default.
• W4386421705 cites W2037900100 @default.
• W4386421705 cites W2087161307 @default.
• W4386421705 cites W2105253056 @default.
• W4386421705 cites W2127059943 @default.
• W4386421705 cites W2884478710 @default.
• W4386421705 cites W2985932978 @default.
• W4386421705 cites W3213700025 @default.
• W4386421705 cites W4221032937 @default.
• W4386421705 doi "https://doi.org/10.33380/2305-2066-2023-12-3-58-65" @default.
• W4386421705 hasPublicationYear "2023" @default.
• W4386421705 type Work @default.
• W4386421705 citedByCount "0" @default.
• W4386421705 crossrefType "journal-article" @default.
• W4386421705 hasAuthorship W4386421705A5004249898 @default.
• W4386421705 hasAuthorship W4386421705A5007962409 @default.
• W4386421705 hasAuthorship W4386421705A5033968842 @default.
• W4386421705 hasAuthorship W4386421705A5039404683 @default.
• W4386421705 hasAuthorship W4386421705A5048247977 @default.
• W4386421705 hasAuthorship W4386421705A5054020101 @default.
• W4386421705 hasAuthorship W4386421705A5058080390 @default.
• W4386421705 hasAuthorship W4386421705A5062675094 @default.
• W4386421705 hasBestOaLocation W43864217051 @default.
• W4386421705 hasConcept C108215921 @default.
• W4386421705 hasConcept C109316439 @default.
• W4386421705 hasConcept C141071460 @default.
• W4386421705 hasConcept C185592680 @default.
• W4386421705 hasConcept C202751555 @default.
• W4386421705 hasConcept C2776125364 @default.
• W4386421705 hasConcept C2776694085 @default.
• W4386421705 hasConcept C2777292972 @default.
• W4386421705 hasConcept C2778119113 @default.
• W4386421705 hasConcept C2778597219 @default.
• W4386421705 hasConcept C43617362 @default.
• W4386421705 hasConcept C55493867 @default.
• W4386421705 hasConcept C71924100 @default.
• W4386421705 hasConcept C98274493 @default.
• W4386421705 hasConceptScore W4386421705C108215921 @default.
• W4386421705 hasConceptScore W4386421705C109316439 @default.
• W4386421705 hasConceptScore W4386421705C141071460 @default.
• W4386421705 hasConceptScore W4386421705C185592680 @default.
• W4386421705 hasConceptScore W4386421705C202751555 @default.
• W4386421705 hasConceptScore W4386421705C2776125364 @default.
• W4386421705 hasConceptScore W4386421705C2776694085 @default.
• W4386421705 hasConceptScore W4386421705C2777292972 @default.
• W4386421705 hasConceptScore W4386421705C2778119113 @default.
• W4386421705 hasConceptScore W4386421705C2778597219 @default.
• W4386421705 hasConceptScore W4386421705C43617362 @default.
• W4386421705 hasConceptScore W4386421705C55493867 @default.
• W4386421705 hasConceptScore W4386421705C71924100 @default.
• W4386421705 hasConceptScore W4386421705C98274493 @default.
• W4386421705 hasIssue "3" @default.
• W4386421705 hasLocation W43864217051 @default.
• W4386421705 hasOpenAccess W4386421705 @default.
• W4386421705 hasPrimaryLocation W43864217051 @default.
• W4386421705 hasRelatedWork W1964909448 @default.
• W4386421705 hasRelatedWork W2032368516 @default.
• W4386421705 hasRelatedWork W2054837357 @default.
• W4386421705 hasRelatedWork W2061251964 @default.
• W4386421705 hasRelatedWork W2081803461 @default.
• W4386421705 hasRelatedWork W2092357016 @default.
• W4386421705 hasRelatedWork W2207220542 @default.
• W4386421705 hasRelatedWork W2368382220 @default.
• W4386421705 hasRelatedWork W2957132482 @default.
• W4386421705 hasRelatedWork W4322733874 @default.
• W4386421705 hasVolume "12" @default.
• W4386421705 isParatext "false" @default.
• W4386421705 isRetracted "false" @default.
• W4386421705 workType "article" @default.